Codexis (CDXS) Operating Income (2010 - 2026)
Codexis (CDXS) posted quarterly Operating Income of -$8.0 million for Q1 2026, up 60.74% year-over-year from -$5.0 million in Q1 2025, and down 176.17% quarter-over-quarter from $10.6 million in Q4 2025.
Codexis (CDXS) Operating Income (2010 - 2026) Analysis & Trends
Codexis' Operating Income history runs 17 years deep, the most recent figure standing at -$8.0 million for Q1 2026.
- In Q1 2026, Operating Income rose 60.74% year-over-year to -$8.0 million; the TTM figure through Mar 2026 stood at -$29.3 million (up 56.35% YoY), while the FY2025 annual figure was -$41.7 million, up 28.67% from the prior year.
- Operating Income for Q1 2026 stood at -$8.0 million, down from $10.6 million in the prior quarter.
- The five-year high for Operating Income was $10.6 million in Q4 2025, with the low at -$32.1 million in Q3 2023.
- The 5-year median for Operating Income is -$12.6 million (2023), against an average of -$12.4 million.
- The sharpest annual moves came in 2024 and 2025: Operating Income slumped 2712.46% in 2024, then surged 243.84% in 2025.
- Codexis' Operating Income stood at -$13.2 million in 2022, then surged by 102.12% to $281000.0 in 2023, then plunged by 2712.46% to -$7.3 million in 2024, then soared by 243.84% to $10.6 million in 2025, then slumped by 176.17% to -$8.0 million in 2026.
- Business Quant data shows CDXS's Operating Income at -$8.0 million in Q1 2026, $10.6 million in Q4 2025, and -$18.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn | -1.55 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn | -375.75 Mn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - | 133.12 Mn |
| 10 | Codexis | 145.23 Mn | 90.31 Mn | 11.40 Mn | -11.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.23 Mn |
| Mar 31, 2026 | -8.04 Mn |
| Dec 31, 2025 | 10.56 Mn |
| Sep 30, 2025 | -18.95 Mn |
| Jun 30, 2025 | -12.86 Mn |
| Mar 31, 2025 | -20.49 Mn |
| Dec 31, 2024 | -7.34 Mn |
| Sep 30, 2024 | -16.56 Mn |
| Jun 30, 2024 | -22.73 Mn |
| Mar 31, 2024 | -11.89 Mn |
| Dec 31, 2023 | 281,000.00 |
| Sep 30, 2023 | -32.06 Mn |
| Jun 30, 2023 | -12.63 Mn |
| Mar 31, 2023 | -23.67 Mn |
| Dec 31, 2022 | -13.25 Mn |
| Sep 30, 2022 | -10.64 Mn |
| Jun 30, 2022 | -2.61 Mn |
| Mar 31, 2022 | -8.39 Mn |
| Dec 31, 2021 | -10.39 Mn |
| Sep 30, 2021 | 1.33 Mn |